These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 33275714)

  • 1. Therapy for lower-risk MDS.
    Carraway HE; Saygin C
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies in low- and high-risk myelodysplastic syndrome.
    Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
    Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
    [No Abstract]   [Full Text] [Related]  

  • 3. Lowering the boom on lower-risk myelodysplastic syndromes.
    Sekeres MA; Patel BJ
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):367-372. PubMed ID: 31808873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How we manage adults with myelodysplastic syndrome.
    Fenaux P; Platzbecker U; Ades L
    Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
    Kang C; Syed YY
    Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
    Park S; Kelaidi C; Meunier M; Casadevall N; Gerds AT; Platzbecker U
    Ann Hematol; 2020 Jan; 99(1):7-19. PubMed ID: 31650290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.
    Della Porta MG; Garcia-Manero G; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcárcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Pilot R; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Prebet T; Lai Y; Degulys A; Paolini S; Cluzeau T; Fenaux P; Platzbecker U
    Lancet Haematol; 2024 Sep; 11(9):e646-e658. PubMed ID: 39038479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
    Li W; Morrone K; Kambhampati S; Will B; Steidl U; Verma A
    Leukemia; 2016 Mar; 30(3):536-44. PubMed ID: 26500138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luspatercept in Myelodysplastic Syndromes: Who and When?
    Komrokji RS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
    Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
    N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
    Sekeres MA; Giagounidis A; Kantarjian H; Mufti GJ; Fenaux P; Jia C; Yang AS; Platzbecker U
    Br J Haematol; 2014 Nov; 167(3):337-45. PubMed ID: 25039607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving therapies for lower-risk myelodysplastic syndromes.
    Bewersdorf JP; Zeidan AM
    Ann Hematol; 2020 Apr; 99(4):677-692. PubMed ID: 32078008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
    Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
    Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
    Molica M; Rossi M
    Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia.
    Feld J; Navada SC; Silverman LR
    Leuk Res; 2020 Oct; 97():106430. PubMed ID: 32763582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation therapy for lower-risk MDS.
    Sébert M
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):59-64. PubMed ID: 38066862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of low-risk myelodysplastic syndromes.
    Santini V
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):462-469. PubMed ID: 27913517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.